跳至主要内容
临床试验/NCT05373810
NCT05373810招募中不适用

Registration Study on Bone and Soft Tissue Sarcoma - An Observational Cohort Study -

Radboud University Medical Center2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2019年7月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
2
主要终点
Progression free survival

研究概览

简要总结

The prospective and retrospective data collection on bone and soft tissue sarcoma is an observational cohort study aimed to collect clinical data and patient reported outcomes of all patients who have been diagnosed with bone or soft tissue sarcoma in the Netherlands. All patients diagnosed with bone or soft tissue sarcoma who are treated, planned for treatment or currently being treated, will be asked to participate in this project.

详细描述

The main objectives of this project are:

  • To improve the knowledge and therefore the treatment care, in patients with bone or soft tissue sarcoma in the Netherlands

  • To start an observational cohort study of bone and soft tissue sarcoma patients from their primary diagnosis until death

  • To prospectively and retrospectively collect data on medical history, co-morbidities, baseline clinical parameters, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, functional outcome, cosmetic outcome, hospital stays and interventions.

  • To collect data on health related quality of life and work ability, to collect data on patient reported outcomes measures.

  • To create a continuous basis for a large variety of research purposes including:

  • Prognostic and predictive research

  • Health care policies and cost-effectiveness studies

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically proven bone or soft tissue sarcoma, excluding Gastrointestinal Stromal Tumours

排除标准

  • Altered mental status that would prohibit the understanding of and giving of informed consent

结局指标

主要结局

Progression free survival

时间窗: up to 10 years

PFS

次要结局

  • grade 3/4 serious adverse events(up to 5 years)
  • Overall survival(up to 10 years)
  • Disease free survival(up to 10 years)
  • Health related quality of life(up to 5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Registration Study Sarcoma | 临床试验